<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754663</url>
  </required_header>
  <id_info>
    <org_study_id>01</org_study_id>
    <nct_id>NCT00754663</nct_id>
  </id_info>
  <brief_title>Exercise Training in Patients With Cardioverter-Defibrillators</brief_title>
  <acronym>BETA</acronym>
  <official_title>BETA: Beneficial Effects of Exercise Training in Patients With Implantable Cardioverter-Defibrillators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exercise therapy has proven to be an effective additive therapy in patients with
      cardiovascular diseases. The prognostic value of physical activity is well established in
      patients with congestive heart failure. Therefore the investigators assumed that the
      population of patients with implantable cardioverter-defibrillators (ICD) with impaired left
      ventricular function may also benefit from a cardiovascular training in terms of improved
      quality of life and reduction of ventricular arrhythmia. The data on feasibility, risk and
      therapeutic effects of exercise training are very limited or not available.

      This prospective randomized study examines the feasibility and benefits of exercise therapy
      in patients with ICD and congestive heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed anamnesis and a clinical examination will be performed in order to determine the
      patient's eligibility for the study. The randomisation either to the exercise- or to the
      control-arm will be performed at baseline. Follow-up visits are planned after four weeks and
      after three months same for both arms. The close-up visit is planned after 6 months.

      The exercise-arm starts off with an introduction into physical training at the Department of
      Sports Medicine at the University in Tübingen. Ergospirometry and 6-min walk test will be
      performed to determine the patients' performance. Then the patients will be encouraged to
      exercise at home. The scales and intensities of physical training will vary interpersonally
      depending on patients individual performance. Pedometers and the ICD-integrated &quot;Cardiac
      Compass&quot; function will be used to verify work load, intensity and duration of the physical
      strain. The patients will be consulted by telephone regularly to affirm the study compliance.
      The physical activity in the control-arm will be monitored using the ICD-integrated &quot;Cardiac
      Compass&quot; function.

      ICD-programming

        -  VT/SVT discrimination &quot;on&quot;,

        -  &quot;Cardiac Compass&quot; feature &quot;on&quot;

        -  VT/VF detection and pacing-programming remain adjusted to clinical situation of the
           patient

      Baseline- and follow-up visits

        -  Anamnesis, NYHA-stadium, patients' demographic data: sex, age, weight, hight,
           concomitant diseases and current medication

        -  Clinical examination: weight, inflow-congestion, edema, pulmonary signs of cardiac
           decompensation

        -  Chest- x-ray (baseline, 6 moths FU)

        -  6-min walk test (baseline, 6 moths FU)

        -  Blood take (baseline, 6 moths FU) standard examinations including blood morphology,
           troponin, renal retention parameters, transaminases)

        -  Determination of the BNP plasma level

        -  Echocardiography (baseline, 6 moths FU): left-ventricular function (EF) and diameter,
           valvular function, estimating of systolic pulmonary arterial pressure (PAP sys.).

        -  Ergospirometry (baseline, 6 moths FU):peak-oxygen-uptake-volume, starting at 10 Watt
           with increase of the work load 12 Watts per minute until the work load capacity has been
           reached. The achieved VO2 value is defined as the 100 % oxygen-uptake. At home the
           patients are supposed to exercise at about 70 % of their VO2 peak.

        -  Measurement/Recording of the peripheral oxygen-uptake of the muscle with
           near-infrared-spectroscopy simultaneously with the bicycle-ergometric exposure.

        -  Complete interrogation of the ICD-memory, acquisition of the &quot;Cardiac-Compass&quot;-data,
           sensing- and threshold-test, recording of electrical impedance and checking of the
           battery-status, impedance and checking of the battery-status

        -  Acquisition of the standardized questionnaires concerning quality-of-life, personality,
           depression and anxiety: PHQ-D, DS14, FSGV 1.0 and GAD-7.

      Definition of adverse event

        -  Adverse event (AE): Any decrease of existential orientation, unwanted incidence,
           subjective or objective symptom of any kind of disease, impairment or any accident, that
           may or may not be connected to the study is defined as an (AE).

        -  Severe adverse event (SAE): A SAE is an event which is life-threatening or deadly,
           causes significant or chronic damage, requires hospitalization or threatens the
           patient's physical inviolability in any other way.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">November 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of arrhythmia burden, heart rate trend, increase in patients activity.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ineffective ICD-interventions, injury risk due to syncope, hospitalization, death. LVEF (echocardiography), VO2max, anaerobic threshold (AT), respiratory compensation point (RCP) and equivalents for O2 and CO2 (ergospirometry) BNP plasma level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>exercise training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control arm: normal behavior, no additional exercise will be advised</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise training</intervention_name>
    <description>walking training at least 3 times a week</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  both gender at a minimum age of 18 years

          -  ICD-systems with &quot;Cardiac-Compass&quot; (Medtronic)-diagnostic feature

          -  ICD system implanted for at least three months

          -  congestive heart failure, NYHA II and III

          -  LVEF ≤ 40 %

          -  compensated state, optimized and stable pharmacological therapy at least for the last
             three months

          -  load capacity of at least 50 watt at baseline.

        Exclusion Criteria:

          -  unable or unwilling to give informed consent

          -  acute coronary syndrome during the past thirty days

          -  hemodynamically relevant valvular defect

          -  instable arterial hypertension

          -  severe COPD

          -  reduced work load capacity caused by instable angina pectoris, peripheral vascular,
             neurological or orthopaedic concomitant disease

          -  hypertrophic obstructive cardiomyopathy (HOCM)

          -  pulmonary-arterial hypertension (PAP systolic ≥ 60 mmHg).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Slawomir Weretka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juergen Schreieck, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Slawomir Weretka, MD</last_name>
    <phone>+49 7071 29 83196</phone>
    <email>weretka@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jurgen Schreieck, MD</last_name>
    <phone>+49 7071 2982711</phone>
    <phone_ext>8781</phone_ext>
    <email>juergen.schreieck@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinic, Dept. of Cardiology</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slawomir Weretka, MD</last_name>
      <phone>+49 7071 29 83196</phone>
      <email>weretka@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jürgen Schreieck, MD</last_name>
      <phone>+49 7071 29 82711</phone>
      <phone_ext>8781</phone_ext>
      <email>juergen.schreieck@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Slawomir Weretka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juergen Schreieck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochen Hansel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konstantinos Stellos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Teufel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Lakka TA, Venäläinen JM, Rauramaa R, Salonen R, Tuomilehto J, Salonen JT. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J Med. 1994 Jun 2;330(22):1549-54.</citation>
    <PMID>8177243</PMID>
  </reference>
  <reference>
    <citation>Schuler G. [Physical activity]. Z Kardiol. 2005;94 Suppl 3:III/11-4. German.</citation>
    <PMID>16258787</PMID>
  </reference>
  <reference>
    <citation>Dürsch M, Schulz O. [Restructuring cardiovascular exercise therapy in Germany with reference to current international guidelines]. Herz. 2003 Aug;28(5):349-58. Review. German.</citation>
    <PMID>12928734</PMID>
  </reference>
  <reference>
    <citation>Schulz O, Dürsch M. [From bench to bicycle. Risk assessment in connection with sports activities and exercise programs in the primary and secondary prevention of cardiovascular diseases]. Herz. 2003 Aug;28(5):359-73. Review. German.</citation>
    <PMID>12928735</PMID>
  </reference>
  <reference>
    <citation>Erbs S, Linke A, Gielen S, Fiehn E, Walther C, Yu J, Adams V, Schuler G, Hambrecht R. Exercise training in patients with severe chronic heart failure: impact on left ventricular performance and cardiac size. A retrospective analysis of the Leipzig Heart Failure Training Trial. Eur J Cardiovasc Prev Rehabil. 2003 Oct;10(5):336-44.</citation>
    <PMID>14663295</PMID>
  </reference>
  <reference>
    <citation>Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, Schoene N, Schuler G. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. JAMA. 2000 Jun 21;283(23):3095-101.</citation>
    <PMID>10865304</PMID>
  </reference>
  <reference>
    <citation>Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999 Mar 9;99(9):1173-82.</citation>
    <PMID>10069785</PMID>
  </reference>
  <reference>
    <citation>Kamke W, Dovifat C, Schranz M, Behrens S, Moesenthin J, Völler H. Cardiac rehabilitation in patients with implantable defibrillators. Feasibility and complications. Z Kardiol. 2003 Oct;92(10):869-75.</citation>
    <PMID>14579052</PMID>
  </reference>
  <reference>
    <citation>Vanhees L, Schepers D, Heidbüchel H, Defoor J, Fagard R. Exercise performance and training in patients with implantable cardioverter-defibrillators and coronary heart disease. Am J Cardiol. 2001 Mar 15;87(6):712-5.</citation>
    <PMID>11249888</PMID>
  </reference>
  <reference>
    <citation>Vanhees L, Kornaat M, Defoor J, Aufdemkampe G, Schepers D, Stevens A, Van Exel H, Van Den Beld J, Heidbüchel H, Fagard R. Effect of exercise training in patients with an implantable cardioverter defibrillator. Eur Heart J. 2004 Jul;25(13):1120-6.</citation>
    <PMID>15231370</PMID>
  </reference>
  <reference>
    <citation>Lampert R, Cannom D, Olshansky B. Safety of sports participation in patients with implantable cardioverter defibrillators: a survey of heart rhythm society members. J Cardiovasc Electrophysiol. 2006 Jan;17(1):11-5.</citation>
    <PMID>16426392</PMID>
  </reference>
  <reference>
    <citation>Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20;112(12):e154-235. Epub 2005 Sep 13.</citation>
    <PMID>16160202</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <last_update_submitted>September 17, 2008</last_update_submitted>
  <last_update_submitted_qc>September 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. med. Slawomir Weretka</name_title>
    <organization>University Hospital Tübingen, Germany</organization>
  </responsible_party>
  <keyword>exercise</keyword>
  <keyword>implantable cardioverter-defibrillator</keyword>
  <keyword>arrhythmia</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

